Transvaginal Mesh
Transvaginal Mesh Highlights
- October 2008: The FDA issued a public health notification alerting healthcare providers of the serious health issues related to the Transvaginal Mesh.
- August 2010: Scientist stop study of transvaginal meshes when 15% of participants experienced erosion of the vaginal wall.

About Transvaginal Mesh
Pelvic Organ Prolapse (POP) is a condition that occurs when a woman’s vaginal wall begins to lose its ability to properly support her bladder, urethra, cervix and rectum. This condition can be brought on by injury, pregnancy and/or surgery and if left untreated can result in organ tissue slipping from the body.
One form of treatment for this condition is the Transvaginal Mesh. This medical device is surgically implanted and stretched across the vaginal wall in order to provide more support and help keep a woman’s organs in their proper place. And, while this device can successfully correct POP it has been associated with some very serious risks.
In August 2010, scientist had to stop a clinical trial on the transvaginal mesh when 15% of the tests subjects experienced erosion of the vaginal wall. This device has also been linked to infection, vaginal scarring and recurrence of POP.
Conditions Treated With Transvaginal Meshes
- Pelvic Organ Prolapse (POP)
- Stress Urinary Incontinence (SUI)
Side Effects & Symptoms
- Erosion of Vaginal Tissue
- Pain
- Infection
- Mesh Erosion
- Urinary Problems
- Vaginal Scarring
- Perforations of the Bowel, Bladder or Blood vessels
- Recurrence of Pelvic Organ Prolapse (POP) and Stress Urinary Incontinence (SUI)
Warnings & Recalls
In October 2008, the FDA issued a public health notification alerting healthcare providers and the public about the increasing number of serious health issues associated with the transvaginal mesh. Reported complications include mesh from nine different manufacturers.





